The Week in Review: December 15 – December 22, 2017

Friday, December 22, 2017 News Recap: Eight Genotypes: Did you know that there are now 8 genotypes and 84 subtypes of HCV that have been identified?  On the one hand this is terrible news; but on the other, a study presented at AASLD 2017 found that Vosevi was effective against them all.  Eight Genotypes and 84 Subtypes of HCV. Telemedicine: Did you know that Project ECHO (Extension for Community Health Outcomes), a fast-growing international tele...

Is Project ECHO the Telemedicine Model That Healthcare Is Missing?

A fast-growing international program, Project ECHO uses telemedicine to help rural and remote providers learn from specialists to manage care for their complex patients. A telemedicine platform developed about 15 years ago in New Mexico is now helping thousands of doctors across the country learn from specialists and manage care for patients with complex conditions. Project ECHO (Extension for Community Health Outcomes) uses a hub-and-spoke model to co

The Week in Review: November 4 – November 10, 2017

Friday, November 10, 2017 News Recap: Canada: Updated List of Physicians in British Columbia Currently Treating Hepatitis B and/or Hepatitis C. HepCBC has updated its list of Doctors in BC who treat HCV and HBV. Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients. Many of the 300,000 HCV-infected Canadians live in under-served and remote areas without access to HCV healthcare specialists. Telemedicine (T...

Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients

Many of the 300,000 HCV-infected Canadians live in under-served and remote areas without access to HCV healthcare specialists. Telemedicine (TM) and advances in HCV management can facilitate linkage of these marginalized patients to healthcare. The TM program described comprises a population that faces many barriers to effective HCV treatment – genotype 3 (25.9% vs. 16.4%),  Indigenous (7.0% vs. 2.2%)  history of injection drug use (70.1% vs. 54.9%) and i